Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Frankfurt (oder) – page 4

61 clinical trials in Frankfurt (oder), Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Frankfurt (oder) at a glance
61
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

61 trials in Frankfurt (oder)

Open in trial search

Study on Atezolizumab with Drug Combination for Patients with Gastric Cancer and Esophagogastric Junction Adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study on Atezolizumab for Patients with High-Risk Stage II or Stage III Colorectal Cancer Not Eligible for Oxaliplatin Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AIO-Studien gGmbH

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Brigimadlin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cholangiocarcinoma+3

Not recruiting

Study of Durvalumab, Tremelimumab, and Capecitabine for Patients with Biliary Tract Cancer in an Adjuvant Setting

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Rectal cancer

Not recruiting

Study Comparing Short Course Radiotherapy and Chemoradiotherapy with Fluorouracil, Calcium Folinate, and Capecitabine for Intermediate and High-Risk Rectal Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Goethe University Frankfurt

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ociperlimab
  • Sponsor:Beigene Ltd.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Frankfurt (oder)

What the registry says about research in the country

01 Hemic and Lymphatic Diseases

Clinical research in Frankfurt (oder) is strongly focused on blood cancers, with studies covering follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, and multiple myeloma. These trials are mainly testing new treatment combinations and comparing them with current standard care to improve response and disease control.

  • New approaches for follicular lymphoma and related indolent lymphomas
  • Treatment studies in relapsed or refractory lymphoma and B-cell non-Hodgkin’s lymphoma
  • Therapy comparisons for chronic lymphocytic leukemia in patients with other health conditions
  • Trials in multiple myeloma and other hematologic cancers

The overall goal is to find safer and more effective options for patients with complex hematologic malignancies, especially where long-term disease control is a priority.

02 Neoplasms

Another major area of trial activity is cancer research in broader tumor types, including diffuse large B-cell lymphoma and other aggressive lymphomas. These studies are evaluating whether newer targeted or combined therapies can improve outcomes for older adults and people who may not tolerate intensive treatment well.

  • Studies for diffuse large B-cell lymphoma and other aggressive B-cell lymphomas
  • Research in older or less fit patients needing gentler treatment options
  • Comparisons of new immunotherapy-based regimens with standard chemotherapy
  • Trials designed to improve remission rates and disease-free survival

This reflects a practical effort to refine treatment choices in oncology, with attention to both effectiveness and tolerability.

03 Nervous System Diseases

Clinical trials in nervous system disease are centered on Alzheimer’s disease, exploring whether an investigational therapy can be safe and well tolerated while also influencing disease-related brain changes. The research aims to support earlier intervention and improve understanding of how treatment may affect the course of memory and cognitive decline.

  • Studies in Alzheimer’s disease at risk and early symptom stages
  • Research on safety and tolerability of a potential new therapy
  • Evaluation of effects on brain amyloid accumulation
  • Work aimed at better treatment strategies for neurodegenerative disease

These trials contribute to efforts in neurology to slow progression and improve future care for people affected by cognitive disorders.

04 Mixed Hematologic and Oncology Research

Several studies in the city also bridge multiple areas of hematology and oncology, including treatment strategies for patients preparing for allogeneic stem cell transplantation. These trials are looking at whether alternative regimens can better control disease before transplant and improve outcomes afterward.

  • Research in higher-risk MDS and oligoblastic AML
  • Treatment planning before allogeneic blood cell transplantation
  • Studies comparing disease control strategies ahead of transplant
  • Focus on improving progression-free and event-free survival

The research supports more tailored treatment pathways for patients with challenging blood disorders and advanced cancer-related conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.